Apyx Medical (APYX) Stock Forecast, Price Target & Predictions
APYX Stock Forecast
Apyx Medical stock forecast is as follows: an average price target of $8.50 (represents a 632.76% upside from APYX’s last price of $1.16) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
APYX Price Target
The average price target for Apyx Medical (APYX) is $8.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $5.00. This represents a potential 632.76% upside from APYX's last price of $1.16.
APYX Analyst Ratings
According to 2 Wall Street analysts, Apyx Medical's rating consensus is 'Buy'. The analyst rating breakdown for APYX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Apyx Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 08, 2022 | - | Lake Street | $5.00 | $1.85 | 170.27% | 331.03% |
| Aug 11, 2022 | Matt O'Brien | Piper Sandler | $12.00 | $10.28 | 16.73% | 934.48% |
| Jul 19, 2022 | - | Lake Street | $17.00 | $8.44 | 101.54% | 1365.52% |
The latest Apyx Medical stock forecast, released on Dec 08, 2022 by Lake Street company, set a price target of $5.00, which represents a 170.27% increase from the stock price at the time of the forecast ($1.85), and a 331.03% increase from APYX last price ($1.16).
Apyx Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.16 | $1.16 | $1.16 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Apyx Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Apyx Medical's last price of $1.16. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 11, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 19, 2022 | Lake Street | Buy | Buy | Hold |
Apyx Medical's last stock rating was published by Piper Sandler on Aug 11, 2022. The company gave APYX a "Overweight" rating, the same as its previous rate.
Apyx Medical Financial Forecast
Apyx Medical Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $14.66M | $15.97M | $17.86M | $12.14M | $12.61M | $9.11M | $10.29M | $12.49M | $16.82M | $11.83M | $11.22M | $8.64M | $11.46M | $6.95M | $4.30M | $5.00M | $8.46M | $7.58M | $6.57M | $5.82M | $9.92M | $8.39M |
| Avg Forecast | $18.24M | $12.73M | $12.88M | $10.74M | $16.83M | $11.76M | $11.75M | $9.53M | $14.85M | $15.37M | $14.33M | $10.84M | $12.94M | $12.01M | $10.56M | $11.12M | $14.63M | $10.20M | $8.86M | $7.84M | $10.27M | $5.69M | $1.97M | $5.20M | $7.86M | $6.78M | $5.87M | $5.67M | $6.61M | $5.59M |
| High Forecast | $20.61M | $14.38M | $14.55M | $12.14M | $19.02M | $13.29M | $13.28M | $10.77M | $16.78M | $17.37M | $16.19M | $12.24M | $14.62M | $13.57M | $11.25M | $11.85M | $15.58M | $10.86M | $9.44M | $8.35M | $10.94M | $6.07M | $2.09M | $5.54M | $8.37M | $7.23M | $6.25M | $6.04M | $7.93M | $6.71M |
| Low Forecast | $16.31M | $11.39M | $11.52M | $9.61M | $15.06M | $10.52M | $10.52M | $8.52M | $13.29M | $13.75M | $12.82M | $9.69M | $11.57M | $10.74M | $10.00M | $10.53M | $13.85M | $9.66M | $8.39M | $7.42M | $9.72M | $5.39M | $1.86M | $4.93M | $7.44M | $6.42M | $5.56M | $5.37M | $5.29M | $4.47M |
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | 0.99% | 1.04% | 1.25% | 1.12% | 0.97% | 0.76% | 0.97% | 1.12% | 1.15% | 1.16% | 1.27% | 1.10% | 1.12% | 1.22% | 2.19% | 0.96% | 1.08% | 1.12% | 1.12% | 1.03% | 1.50% | 1.50% |
Apyx Medical's average Quarter revenue forecast for Mar 24 based on 1 analysts is $9.53M, with a low forecast of $8.52M, and a high forecast of $10.77M. APYX's average Quarter revenue forecast represents a -35.02% decrease compared to the company's last Quarter revenue of $14.66M (Dec 23).
Apyx Medical EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | $-5.62M | $-4.64M | $-1.24M | $-5.57M | $-5.91M | $-5.53M | $-5.10M | $-5.67M | $-1.64M | $-3.91M | $-3.72M | $-4.60M | $-1.69M | $-4.20M | $-5.95M | $-6.64M | $-5.81M | $-3.62M | $-3.74M | $-4.19M | $-691.00K | $-1.47M |
| Avg Forecast | $-9.46M | $-6.60M | $-6.68M | $-5.57M | $-8.73M | $-6.10M | $-6.10M | $-4.94M | $-7.70M | $-7.97M | $-7.43M | $-5.62M | $-6.71M | $-5.16M | $-5.48M | $-4.89M | $-7.59M | $-5.29M | $-4.60M | $-4.60M | $-5.32M | $-2.95M | $-1.02M | $-10.51M | $-4.08M | $-3.52M | $-3.04M | $-5.64M | $-380.05K | $-809.05K |
| High Forecast | $-8.46M | $-5.91M | $-5.97M | $-4.98M | $-7.81M | $-5.46M | $-5.45M | $-4.42M | $-6.89M | $-7.13M | $-6.65M | $-5.03M | $-6.00M | $-4.13M | $-5.19M | $-3.91M | $-7.18M | $-5.01M | $-4.35M | $-3.68M | $-5.04M | $-2.80M | $-965.19K | $-8.41M | $-3.86M | $-3.33M | $-2.88M | $-4.51M | $-304.04K | $-647.24K |
| Low Forecast | $-10.69M | $-7.46M | $-7.55M | $-6.29M | $-9.86M | $-6.89M | $-6.89M | $-5.58M | $-8.71M | $-9.01M | $-8.40M | $-6.35M | $-7.58M | $-6.20M | $-5.83M | $-5.87M | $-8.08M | $-5.63M | $-4.90M | $-5.52M | $-5.67M | $-3.15M | $-1.09M | $-12.61M | $-4.34M | $-3.75M | $-3.24M | $-6.76M | $-456.06K | $-970.86K |
| Surprise % | - | - | - | - | - | - | - | - | 0.73% | 0.58% | 0.17% | 0.99% | 0.88% | 1.07% | 0.93% | 1.16% | 0.22% | 0.74% | 0.81% | 1.00% | 0.32% | 1.42% | 5.84% | 0.63% | 1.43% | 1.03% | 1.23% | 0.74% | 1.82% | 1.82% |
undefined analysts predict APYX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Apyx Medical's previous annual EBITDA (undefined) of $NaN.
Apyx Medical Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 | 11 |
| Net Income | - | - | - | - | - | - | - | - | $-9.61M | $-4.63M | $-994.00K | $-3.53M | $-6.07M | $-5.79M | $-5.45M | $-5.97M | $-2.01M | $-4.22M | $-4.05M | $-4.90M | $-1.53M | $-3.73M | $-4.69M | $-1.95M | $-5.81M | $-4.31M | $-4.34M | $-4.68M | $-935.00K | $-1.69M |
| Avg Forecast | $-5.11M | $-5.63M | $-5.80M | $-5.98M | $-4.09M | $-6.24M | $-6.86M | $-7.48M | $-6.17M | $-3.95M | $-2.43M | $-4.68M | $-4.94M | $-5.57M | $-6.50M | $-5.15M | $-3.81M | $-5.20M | $-5.11M | $-4.90M | $-3.72M | $-5.72M | $-7.36M | $-3.09M | $-6.67M | $-6.24M | $-6.06M | $-5.72M | $-514.25K | $-926.75K |
| High Forecast | $-4.41M | $-4.86M | $-5.01M | $-5.16M | $-3.53M | $-5.38M | $-5.92M | $-6.46M | $-5.22M | $-3.41M | $-2.09M | $-4.04M | $-4.26M | $-4.46M | $-6.05M | $-4.12M | $-3.55M | $-4.84M | $-4.76M | $-3.92M | $-3.47M | $-5.32M | $-6.86M | $-2.47M | $-6.21M | $-5.81M | $-5.65M | $-4.58M | $-411.40K | $-741.40K |
| Low Forecast | $-5.97M | $-6.58M | $-6.78M | $-6.99M | $-4.78M | $-7.29M | $-8.02M | $-8.75M | $-7.12M | $-4.62M | $-2.83M | $-5.47M | $-5.77M | $-6.69M | $-7.05M | $-6.18M | $-4.13M | $-5.64M | $-5.54M | $-5.88M | $-4.04M | $-6.20M | $-7.99M | $-3.71M | $-7.24M | $-6.77M | $-6.58M | $-6.87M | $-617.10K | $-1.11M |
| Surprise % | - | - | - | - | - | - | - | - | 1.56% | 1.17% | 0.41% | 0.76% | 1.23% | 1.04% | 0.84% | 1.16% | 0.53% | 0.81% | 0.79% | 1.00% | 0.41% | 0.65% | 0.64% | 0.63% | 0.87% | 0.69% | 0.72% | 0.82% | 1.82% | 1.82% |
Apyx Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. APYX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Apyx Medical SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 | 11 |
| SG&A | - | - | - | - | - | - | - | - | $8.59M | $4.84M | $5.38M | $12.06M | $12.92M | $10.48M | $11.82M | $12.93M | $12.90M | $10.85M | $10.49M | $9.49M | $8.84M | $8.05M | $7.29M | $9.50M | $10.92M | $8.78M | $8.05M | $8.11M | $7.96M | $7.66M |
| Avg Forecast | $18.39M | $12.84M | $12.99M | $10.83M | $16.98M | $11.86M | $11.86M | $9.61M | $14.98M | $15.50M | $14.45M | $10.93M | $13.05M | $12.11M | $10.65M | $11.22M | $14.75M | $10.28M | $8.94M | $7.91M | $10.35M | $5.74M | $1.98M | $5.25M | $7.92M | $6.84M | $5.92M | $5.72M | $2.91M | $2.89M |
| High Forecast | $20.78M | $14.51M | $14.67M | $12.24M | $19.18M | $13.40M | $13.40M | $10.86M | $16.93M | $17.52M | $16.33M | $12.35M | $14.74M | $13.69M | $11.34M | $11.95M | $15.72M | $10.96M | $9.52M | $8.42M | $11.03M | $6.12M | $2.11M | $5.59M | $8.44M | $7.29M | $6.31M | $6.09M | $3.49M | $3.47M |
| Low Forecast | $16.45M | $11.49M | $11.62M | $9.69M | $15.19M | $10.61M | $10.61M | $8.60M | $13.40M | $13.87M | $12.93M | $9.78M | $11.67M | $10.84M | $10.08M | $10.62M | $13.97M | $9.74M | $8.46M | $7.49M | $9.81M | $5.44M | $1.88M | $4.97M | $7.51M | $6.48M | $5.61M | $5.42M | $2.33M | $2.31M |
| Surprise % | - | - | - | - | - | - | - | - | 0.57% | 0.31% | 0.37% | 1.10% | 0.99% | 0.86% | 1.11% | 1.15% | 0.87% | 1.05% | 1.17% | 1.20% | 0.85% | 1.40% | 3.68% | 1.81% | 1.38% | 1.28% | 1.36% | 1.42% | 2.74% | 2.65% |
Apyx Medical's average Quarter SG&A projection for Mar 24 is $9.61M, based on 1 Wall Street analysts, with a range of $8.60M to $10.86M. The forecast indicates a 11.86% rise compared to APYX last annual SG&A of $8.59M (Dec 23).
Apyx Medical EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 | 11 |
| EPS | - | - | - | - | - | - | - | - | $-0.28 | $-0.13 | $-0.03 | $-0.10 | $-0.18 | $-0.17 | $-0.16 | $-0.17 | $-0.06 | $-0.12 | $-0.12 | $-0.14 | $-0.04 | $-0.11 | $-0.14 | $-0.06 | $-0.16 | $-0.13 | $-0.13 | $-0.14 | $-0.03 | $-0.05 |
| Avg Forecast | $-0.15 | $-0.16 | $-0.17 | $-0.17 | $-0.12 | $-0.18 | $-0.20 | $-0.22 | $-0.18 | $-0.11 | $-0.07 | $-0.14 | $-0.14 | $-0.14 | $-0.19 | $-0.15 | $-0.11 | $-0.15 | $-0.15 | $-0.14 | $-0.11 | $-0.17 | $-0.21 | $-0.25 | $-0.19 | $-0.18 | $-0.17 | $-0.18 | $-0.01 | $-0.03 |
| High Forecast | $-0.13 | $-0.14 | $-0.14 | $-0.15 | $-0.10 | $-0.16 | $-0.17 | $-0.19 | $-0.15 | $-0.10 | $-0.06 | $-0.12 | $-0.12 | $-0.13 | $-0.17 | $-0.14 | $-0.10 | $-0.14 | $-0.14 | $-0.14 | $-0.10 | $-0.15 | $-0.20 | $-0.23 | $-0.18 | $-0.17 | $-0.16 | $-0.17 | $-0.01 | $-0.02 |
| Low Forecast | $-0.17 | $-0.19 | $-0.20 | $-0.20 | $-0.14 | $-0.21 | $-0.23 | $-0.25 | $-0.21 | $-0.13 | $-0.08 | $-0.16 | $-0.17 | $-0.17 | $-0.20 | $-0.16 | $-0.12 | $-0.16 | $-0.16 | $-0.16 | $-0.12 | $-0.18 | $-0.23 | $-0.27 | $-0.21 | $-0.20 | $-0.19 | $-0.19 | $-0.01 | $-0.03 |
| Surprise % | - | - | - | - | - | - | - | - | 1.57% | 1.14% | 0.43% | 0.74% | 1.26% | 1.17% | 0.85% | 1.16% | 0.53% | 0.80% | 0.81% | 0.97% | 0.37% | 0.67% | 0.66% | 0.24% | 0.83% | 0.72% | 0.74% | 0.79% | 3.00% | 1.93% |
According to undefined Wall Street analysts, Apyx Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to APYX previous annual EPS of $NaN (undefined).
Apyx Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APYX | Apyx Medical | $1.16 | $8.50 | 632.76% | Buy |
| INGN | Inogen | $11.33 | $26.00 | 129.48% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| LIVN | LivaNova | $48.53 | $71.25 | 46.82% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| AORT | Artivion | $25.25 | $30.00 | 18.81% | Buy |
| AVNS | Avanos Medical | $24.00 | $27.00 | 12.50% | Hold |
| SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
APYX Forecast FAQ
Is Apyx Medical a good buy?
Yes, according to 2 Wall Street analysts, Apyx Medical (APYX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of APYX's total ratings.
What is APYX's price target?
Apyx Medical (APYX) average price target is $8.5 with a range of $5 to $12, implying a 632.76% from its last price of $1.16. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Apyx Medical stock go up soon?
According to Wall Street analysts' prediction for APYX stock, the company can go up by 632.76% (from the last price of $1.16 to the average price target of $8.5), up by 934.48% based on the highest stock price target, and up by 331.03% based on the lowest stock price target.
Can Apyx Medical stock reach $2?
APYX's average twelve months analyst stock price target of $8.5 supports the claim that Apyx Medical can reach $2 in the near future.
What are Apyx Medical's analysts' financial forecasts?
Apyx Medical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $49.87M (high $56.35M, low $44.62M), average EBITDA is $-25.865M (high $-23.14M, low $-29.227M), average net income is $-24.667M (high $-21.288M, low $-28.835M), average SG&A $50.3M (high $56.84M, low $45M), and average EPS is $-0.712 (high $-0.614, low $-0.832). APYX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $54.58M (high $61.68M, low $48.83M), average EBITDA is $-28.308M (high $-25.326M, low $-31.988M), average net income is $-22.519M (high $-19.434M, low $-26.324M), average SG&A $55.05M (high $62.21M, low $49.25M), and average EPS is $-0.65 (high $-0.561, low $-0.76).
Did the APYX's actual financial results beat the analysts' financial forecasts?
Based on Apyx Medical's last annual report (Dec 2023), the company's revenue was $52.35M, which missed the average analysts forecast of $55.38M by -5.48%. Apple's EBITDA was $-19.259M, missing the average prediction of $-28.725M by -32.95%. The company's net income was $-18.713M, beating the average estimation of $-17.218M by 8.68%. Apple's SG&A was $29.23M, missing the average forecast of $55.86M by -47.68%. Lastly, the company's EPS was $-0.54, beating the average prediction of $-0.497 by 8.65%. In terms of the last quarterly report (Dec 2023), Apyx Medical's revenue was $14.66M, missing the average analysts' forecast of $14.85M by -1.29%. The company's EBITDA was $-5.624M, missing the average prediction of $-7.704M by -27.00%. Apyx Medical's net income was $-9.607M, beating the average estimation of $-6.167M by 55.79%. The company's SG&A was $8.59M, missing the average forecast of $14.98M by -42.66%. Lastly, the company's EPS was $-0.28, beating the average prediction of $-0.178 by 57.30%